MASA Valve Early Feasibility Study for Congenital Heart Defects
This study is testing a new device called the MASA Valve. It's designed to help children and young adults (up to 22 years old) who have certain heart conditions like Tetralogy of Fallot or Pulmonary Stenosis. The MASA Valve replaces a faulty pulmonary valve or a previously implanted device, helping blood flow correctly from the heart to the lungs. The main goal of this early study is to see if the MASA Valve is safe and works as intended, specifically looking at whether patients avoid device-related death, needing the device removed, or needing another surgery related to the device, all within one year. We are looking for about 10 participants for this study.
- Study design
- This is an interventional study, meaning participants will receive the MASA Valve. It aims to enroll about 10 participants.
- What's involved
- You would undergo surgery to replace your pulmonary valve with the MASA Valve. You would also need to return for follow-up appointments for one year after the surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year after the surgery to assess the device's safety and effectiveness.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
MASA Valve Early Feasibility Study
At a glance
Conditions
NCT05452720
Where you'd take part
This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Boston Childrens Hospital
Boston, Massachusettsstudy coordinator listed
Recruiting
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvaniastudy coordinator listed
Recruiting
Childrens Medical Center Dallas
Dallas, Texasstudy coordinator listed
Recruiting
Cincinnati Children's Hospital
Cincinnati, Ohiostudy coordinator listed
Recruiting
OSF Childrens Hospital of Illinois
Peoria, Illinoisstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- David Morales, MD · PRINCIPAL_INVESTIGATOR · Cinncinnati Childrens Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Freedom from device related death1 year
Percentage of patients that have not died related to the device 1 year from implantation
- Freedom from Explant1 year
Percentage of patients that have not undergone device explant within 1 year from implantation
- Freedom from Device-Related Reoperation1 year
Percentage of patients that have not undergone re-operation related to the device within 1 year from implantation
- Freedom from Device-Related Catheter Intervention1 year
Percentage of patients that have not undergone device related catheter based intervention within 1 year from implantation
- Freedom from Endocarditis1 year
Percentage of patients that have not had endocarditis within 1 year from implantation
- Freedom from Thrombus1 year
Percentage of patients that have not had a serious thrombotic event related to the device within 1 year from implantation
- Freedom from Major Hemorrhage1 year
Percentage of patients that have not had a major bleeding episode related to the device within 1 year from implantation